Barclays
PLRX icon

Barclays’s Pliant Therapeutics PLRX Stock Holding History

Barclays’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-30,000
Closed -$336K – 5426
2024
Q3 		$336K Buy
+30,000
New +$375K ﹤0.01% 4017

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Barclays's PLRX Position: Q2 2026 in Review

Barclays increased its Pliant Therapeutics (PLRX) stake by 1,153% in Q2 2026, buying an estimated $477 and bringing the position to 426 shares worth $486. The position accounts for ﹤0.01% of the portfolio, ranked #5011.

Barclays first reported a position in PLRX in Q1 2022 and has held it in 18 quarters since. The position peaked at $6.39M in Q4 2023. 86 funds tracked by Wall St. Rank hold PLRX as of Q2 2026.

  • Barclays held 426 shares of Pliant Therapeutics worth $486 as of Q2 2026.
  • Barclays bought 392 Pliant Therapeutics shares in Q2 2026, an estimated $477.
  • Pliant Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5011 holding.
  • Barclays first reported a position in Pliant Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Pliant Therapeutics position peaked at $6.39M in Q4 2023.
  • 86 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.